{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:12:37Z","timestamp":1792811557005,"version":"4.5.0"},"reference-count":13,"publisher":"VM Media SP. zo.o VM Group SK","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologia i Neurochirurgia Polska"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.pjnns.2017.01.010","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T12:04:08Z","timestamp":1486123448000},"page":"194-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy"],"prefix":"10.5603","volume":"51","author":[{"given":"Claudia","family":"St\u00f6llberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Finsterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3595","reference":[{"issue":"26","key":"10.1016\/j.pjnns.2017.01.010_bib0070","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pjnns.2017.01.010_bib0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pjnns.2017.01.010_bib0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pjnns.2017.01.010_bib0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pjnns.2017.01.010_bib0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eplepsyres.2016.06.003","article-title":"Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs","volume":"126","author":"St\u00f6llberger","year":"2016","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.pjnns.2017.01.010_bib0095","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1160\/TH13-10-0871","article-title":"Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"111","author":"Francart","year":"2014","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pjnns.2017.01.010_bib0100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pjnns.2017.01.010_bib0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.pjnns.2017.01.010_bib0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"Interactions of warfarin with drugs and food","volume":"121","author":"Wells","year":"1994","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.pjnns.2017.01.010_bib0115","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/jth.13268","article-title":"The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population","volume":"14","author":"Mannheimer","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"52","key":"10.1016\/j.pjnns.2017.01.010_bib0120","first-page":"A6568","article-title":"Pulmonary embolism due to interaction between rivaroxaban and carbamazepine","volume":"157","author":"Risselada","year":"2013","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.pjnns.2017.01.010_bib0125","unstructured":"European Medicines Agency: 15\/09\/2016 Xarelto \u2013 EMEA\/H\/C\/000944\/II\/0042\/G."},{"key":"10.1016\/j.pjnns.2017.01.010_bib0130","first-page":"1","article-title":"Laboratory monitoring of rivaroxaban and assessment of its bleeding risk","author":"Zhang","year":"2016","journal-title":"Br J Biomed Sci"}],"container-title":["Neurologia i Neurochirurgia Polska"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028384317300439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028384317300439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T05:44:35Z","timestamp":1546926275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028384317300439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0028384317300439"],"URL":"https:\/\/doi.org\/10.1016\/j.pjnns.2017.01.010","relation":{},"ISSN":["0028-3843"],"issn-type":[{"value":"0028-3843","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neurologia i Neurochirurgia Polska","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pjnns.2017.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}